

Orlova Ya.A.<sup>1</sup>, Mareev Yu.V.<sup>1,2</sup>, Mareev V. Yu.<sup>1</sup>, Plisyk A.G.<sup>1</sup>, Begrambekova Yu.L.<sup>1</sup>, Akopyan Z.A.<sup>1</sup>, Sakaeva D. M.<sup>1</sup>, Loginova D. D.<sup>1</sup>, Shurygina A. S.<sup>1</sup>, Kamalov A. A.<sup>1</sup>

## THE BURDEN OF RESIDUAL SYMPTOMS THAT COMPLICATE THE LIFE OF PATIENTS WHO HAVE SUFFERED A NEW CORONAVIRUS INFECTION (THROW STUDY)

## SUPPLEMENTAL MATERIALS

Table 1a. The THROW Study Questionnaire

#	Question	During hospital treatment		Now	
		Yes	No	Yes	No
1	Have you had a cough?				
2	Have you noticed a fever of more than 37.0 °C?				
3	Have you experienced shortness of breath?				
4	Have you had any chest pains?				
5	Have you noticed a loss/weakening of taste?				
6	Have you noticed a loss/weakening of sense of smell?				
7	Have you complained of fatigue or weakness?				
8	Have you had nausea or vomiting?				
9	Have you complained of muscle pain?				
10	Have you ever complained of joint pain?				
11	Have you complained of headache?				
12	Have you noticed any skin rash or redness?				
13	Have you had diarrhea??				
14	Have you ever complained of abdominal pain?				
15	Have you had a need to get extra rest during the day when you were discharged from the hospital? If so, do you still have it?				

Table 2a. Comparative characteristics of the respondents (n = 159) by the main parametric indicators obtained at the screening

Parameter	Total number of patients (n = 159)	Subjects of the survey (n = 98)	Patients who refused to participate in the survey $(n = 61)$	p
Age, years	56.4 ± 14.5	$55.5 \pm 14.2$	58.0 ± 14.9	0.284
Male	88 (55.3)	56 (57.1)	32 (52.5)	0.679
BMI, kg/m <sup>2</sup>	29.2 [25.7; 32.8]	29.0 [25.5; 32.3]	29.8 [26.4; 33.6]	0.267
Obesity (BMI > 30 kg/m <sup>2</sup> )	67 (43.5)	42 (43.8)	25 (43.1)	1.000
Arterial hypertension	74 (46.8)	44 (45.4)	30 (49.2)	0.761
CAD	14 (8.86)	11 (11.3)	3 (4.92)	0.273
Diabetes mellitus	20 (12.7)	13 (13.4)	7 (11.5)	0.874
Cancer	6 (3.82)	2 (2.08)	4 (6.56)	0.210
Body temperature, °C	37.3 [36.6; 37.8]	37.3 [36.7; 37.9]	37.0 [36.5; 37.7]	0.129
RR, breaths per min	19.0 [18.0; 20.0]	19.0 [18.0; 20.0]	18.0 [17.0; 20.0]	0.594
HR, bpm	87.1 ± 14.9	$87.8 \pm 15.0$	$86.0 \pm 14.7$	0.441
SBP, mm Hg	120 [115; 130]	120 [115; 132]	120 [112; 130]	0.131
SO <sub>2</sub> , %	96.0 [93.8; 98.0]	95.0 [94.0; 98.0]	96.0 [93.0; 98.0]	0.692
Any oxygen support	39 (24.7)	24 (24.5)	15 (25.0)	1.000
CRP, mg/dL	48.1 [14.8; 98.0]	51.2 [13.2; 99.0]	41.6 [15.7; 97.4]	0.963
D-dimer, μg/mL	0.54 [0.34; 0.98]	0.50 [0.30; 0.96]	0.63 [0.38; 1.03]	0.276
Lymphocytes, × 10 <sup>9</sup> /L	1.22 [0.90; 1.61]	1.17 [0.84; 1.56]	1.32 [0.99; 1.66]	0.127
Neutrophils, × 10 <sup>9</sup> /L	3.65 [2.60; 4.92]	4.07 [2.59; 5.07]	3.11 [2.62; 4.71]	0.677
GFR (CKD EPI), mL/min/1.73 m <sup>2</sup>	77.0 [62.0; 88.0]	74.0 [61.0; 87.0]	78.0 [62.8; 94.2]	0.260

<sup>&</sup>lt;sup>1</sup> Lomonosov Moscow State University, Moscow, Russia

<sup>&</sup>lt;sup>2</sup> National Medical Research Center of Therapy and Preventive Medicine, Moscow, Russia



Glucose, mmol/L	5.80 [5.23; 6.57]	5.88 [5.30; 6.54]	5.64 [5.14; 6.82]	0.611
CT stage				
1	108 (71.1)	64 (70.3)	44 (72.1)	
2	32 (21.1)	20 (22.0)	12 (19.7)	0.77.1
3	11 (7.24)	7 (7.69)	4 (6.56)	0.761
4	1 (0.66)	0	1 (1.64)	
SHOCS-COVID score	5.00 [4.00; 7.00]	5.00 [3.25; 7.00]	5.00 [4.00; 7.00]	0.695
NEWS-2 score	3.00 [1.00; 5.00]	3.00 [1.00; 5.00]	3.00 [1.50; 5.00]	0.673

Parametric quantitative indicators are expressed as the means and standard deviations (M±SD), non-parametric indicators are presented as the medians and interquartile ranges (Me [25<sup>th</sup> percentile; 75<sup>th</sup> percentile], qualitative indicators are expressed as the absolute numbers and percentages (n (%)). BMI, body mass index; CAD, coronary artery disease; RR, respiratory rate; HR, heart rate; SBP, systolic blood pressure; SO<sub>2</sub>, blood oxygen saturation; CRP, C-reactive protein; GFR, glomerular filtration rate; NLR, neutrophil-to-lymphocyte ratio; LCR, lymphocyte-to-C-reactive protein ratio; CT, computed tomography; SHOCS-COVID, Symptomatic Hospital and Outpatient Clinical score for COVID-19; NEWS-2, National Early Warning Score 2.

**Table 3a.** Comparative characteristics of patients by the incidence of symptoms at discharge and after eight months, grouped according to sex

Symptoms reported during telephone survey	Total number of subjects (n = 98)	Female (n = 42)	Male (n = 56)	p
Cough at admission	58 (59.2)	30 (71.4)	28 (50.0)	0.054
Cough in 8 months	4 (4.08)	3 (7.14)	1 (1.79)	0.317
Fever at admission	83 (84.7)	35 (83.3)	48 (85.7)	0.968
Fever in 8 months	5 (5.10)	3 (7.14)	2 (3.57)	0.642
Dyspnea at admission	49 (50.0)	22 (52.4)	27 (48.2)	0.838
Dyspnea in 8 months	22 (22.4)	14 (33.3)	8 (14.3)	0.046
Chest pain at admission	29 (29.6)	16 (38.1)	13 (23.2)	0.170
Chest pain in 8 months	5 (5.10)	2 (4.76)	3 (5.36)	1.000
Loss of taste at admission	46 (46.9)	17 (40.5)	29 (51.8)	0.365
Loss of taste in 8 months	7 (7.14)	5 (11.9)	2 (3.57)	0.234
Anosmia at admission	48 (49.0)	21 (50.0)	27 (48.2)	1.000
Anosmia in 8 months	15 (15.3)	9 (21.4)	6 (10.7)	0.240
Asthenia at admission	85 (86.7)	39 (92.9)	46 (82.1)	0.213
Asthenia in 8 months	27 (27.6)	18 (42.9)	9 (16.1)	0.007
Vomiting at admission	17 (17.3)	14 (33.3)	3 (5.36)	0.001
Vomiting in 8 months	2 (2.04)	2 (4.76)	0 (0.00)	0.187
Myalgia at admission	38 (38.8)	22 (52.4)	16 (28.6)	0.029
Myalgia in 8 months	17 (17.3)	10 (23.8)	7 (12.5)	0.233
Arthralgia at admission	37 (37.8)	20 (47.6)	17 (30.4)	0.125
Arthralgia in 8 months	21 (21.4)	14 (33.3)	7 (12.5)	0.025
Cephalalgia at admission	40 (40.8)	21 (50.0)	19 (33.9)	0.163
Cephalalgia in 8 months	12 (12.2)	11 (26.2)	1 (1.79)	0.001
Rash at admission	9 (9.18)	6 (14.3)	3 (5.36)	0.169
Rash in 8 months	8 (8.16)	7 (16.7)	1 (1.79)	0.012
Diarrhea at admission	36 (36.7)	21 (50.0)	15 (26.8)	0.032
Diarrhea in 8 months	5 (5.10)	3 (7.14)	2 (3.57)	0.642
Abdominal pain at admission	16 (16.3)	8 (19.0)	8 (14.3)	0.723
Abdominal pain in 8 months	6 (6.12)	4 (9.52)	2 (3.57)	0.390
Fatigue at admission	73 (74.5)	33 (78.6)	40 (71.4)	0.570
Fatigue in 8 months	30 (30.6)	18 (42.9)	12 (21.4)	0.040
Total number of complains at admission	$6.78 \pm 2.91$	$7.74 \pm 3.12$	$6.05 \pm 2.53$	0.005
Total number of complains in 8 months	1.00 [0.00; 3.00]	2.00 [1.00; 4.75]	0.00 [0.00; 2.00]	< 0.001
Presence of complains in 8 months	59 (60.2)	32 (76.2)	27 (48.2)	0.010

Parametric quantitative indicators are expressed as the means and standard deviations ( $M \pm SD$ ), non-parametric indicators are presented as the medians and interquartile ranges (Me [ $25^{th}$  percentile;  $75^{th}$  percentile], qualitative indicators are expressed as the absolute numbers and percentages (n (%)). BMI, body mass index; CAD, coronary artery disease; RR, respiratory rate; HR, heart rate; SBP, systolic blood pressure;  $SO_2$ , blood oxygen saturation; CRP, C-reactive protein; GFR, glomerular filtration rate; NLR, neutrophil-to-lymphocyte ratio; LCR, lymphocyte-to-C-reactive protein ratio; CT, computed tomography; SHOCS-COVID, Symptomatic Hospital and Outpatient Clinical score for COVID-19; NEWS-2, National Early Warning Score 2.